Provention Bio, Inc.
PRVB · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $13 | $1 | $0 | $0 |
| % Growth | 824.4% | – | – | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $12 | $1 | $0 | $0 |
| % Margin | 96% | 100% | – | – |
| R&D Expenses | $76 | $70 | $66 | $36 |
| G&A Expenses | $64 | $47 | $33 | $8 |
| SG&A Expenses | $64 | $47 | $33 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $141 | $117 | $100 | $44 |
| Operating Income | -$128 | -$116 | -$100 | -$44 |
| % Margin | -993.9% | -8,285.2% | – | – |
| Other Income/Exp. Net | $1 | $0 | $1 | $1 |
| Pre-Tax Income | -$127 | -$115 | -$99 | -$43 |
| Tax Expense | -$13 | -$1 | -$1 | -$1 |
| Net Income | -$114 | -$114 | -$99 | -$42 |
| % Margin | -880.7% | -8,203% | – | – |
| EPS | -1.52 | -1.81 | -1.88 | -1.04 |
| % Growth | 16% | 3.7% | -80.8% | – |
| EPS Diluted | -1.52 | -1.81 | -1.88 | -1.04 |
| Weighted Avg Shares Out | 75 | 63 | 52 | 41 |
| Weighted Avg Shares Out Dil | 75 | 63 | 52 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $1 | $1 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $0 | $0 | -$0 |
| EBITDA | -$125 | -$115 | -$100 | -$44 |
| % Margin | -967% | -8,257.4% | – | – |